Product Description
Merck was developing mk-8245, an oral SCD Inhibitor for Type 2 Diabetes Mellitus. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00972322)
Mechanisms of Action: SCD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00972322 |
MK-8245-012 | P1 |
Completed |
Type 2 Diabetes |
2010-01-12 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00790556 |
NCT00790556 | P1 |
Completed |
Type 2 Diabetes |
2009-09-01 |
2022-05-04 |
Primary Endpoints |
|
2008-005817-23 |
2008-005817-23 | P2 |
Terminated |
Type 2 Diabetes |
2009-08-20 |
2022-03-12 |
Treatments |
|
NCT00846391 |
MK8245-005 AM2 | P2 |
Terminated |
Type 2 Diabetes |
2009-08-01 |
2022-05-04 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|